Castle Biosciences CEO Derek Maetzold disposes of USD 581,331 in common shares - CSTL News | RalliesCastle Biosciences CEO Derek Maetzold disposes of USD 581,331 in common shares
C
CSTL• CEO reports option exercise and share sales
- Castle Biosciences CEO Derek J. Maetzold reported a stock option exercise on Aug. 28, 2026 for 12,428 shares at USD 2.39.
- He sold 11,472 shares at a weighted-average USD 33.14, leaving 22,435 shares held directly.
- He also sold 956 shares at a weighted-average USD 33.88, reducing direct holdings to 21,479 shares.
•
